Kura Oncology (KURA)

• Market cap: $784M
• 1 day: 0.91%
• 5 days: -5.46%
• 1 month: 14.23%
• 3 months: 8.74%
• 6 months: -15.42%
• Year to date: -14.6%
• 1 year: 34.6%
• 5 years: -67.21%
• 10 years: 178.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

Employees: 260